

REMARKS

The specification has been amended to reflect the national stage status.

In addition, the claims have been amended to remove multiple dependencies in order to reduce the PTO filing fee.

Additional amendments have been made to place the application in conformance with U.S. practice, such as the addition of a pharmaceutically acceptable carrier to the composition claims, which is supported on pages 59-66.

Favorable action on the merits is solicited.

Respectfully submitted,

Hiromu HABASHITA et al.

By Warren Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 22, 2006